A research alliance of Heidelberg University Hospital and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), jointly with colleagues of the Helmholtz Center for Environmental Research in Leipzig, have discovered a new metabolic pathway which makes malignant brain tumors (gliomas) more aggressive and weakens patients’ immune systems. Using drugs to inhibit this metabolic pathway is a new approach in cancer treatment. The group’s results have been published in the prestigious specialist journal Nature.
In brain tumor tissue, it is possible to detect both the enzyme TDO (red) and the dioxin receptor AHR (brown) in the same regions. (Staining: Felix Sahm, Neuropathology Dept., Heidelberg University Hospitals. Picture: “Nature”).
Glioma is the most frequent and most malignant brain tumor in adults. In Germany, about 4,500 people are newly diagnosed with glioma every year. About 75 percent of such tumors are considered particularly aggressive with an average life expectancy of eight months to two years. The standard treatment is surgery to remove the tumor as completely as possible, followed by radiotherapy, usually in combination with chemotherapy. However, results are unsatisfactory, because these tumors are very resilient and soon start growing back. Therefore, there is an urgent need for new treatment approaches.
Tumors grow more aggressively and immune system is weakened
The Helmholtz Junior Research Group “Experimental Neuroimmunology” led by Professor Dr. Michael Platten of DKFZ and the Department of Neurooncology of Heidelberg University Hospital and the National Center for Tumor Diseases (NCT) headed by Professor Dr. Wolfgang Wick have come across the kynurenin molecule in their studies of human cancer cells and in the mouse model. Kynurenin is formed when the amino acid tryptophan – a protein component taken in with food – is broken down in the body. “We have been able to detect increased levels of kynurenin in cancer cells of glioma patients with particularly aggressive tumors,” Professor Michael Platten explained. The current research results from Heidelberg show that this link also appears to exist in other types of cancer such as cancers of the bladder, bowel or lungs.
It was even more astonishing for the investigators to find that kynurenin activates a protein known as dioxin receptor. This, in turn, triggers a cascade of chemical reactions which ultimately promote tumor growth and weaken the immune system. So far, it had only been known that the dioxin receptor, scientifically called aryl hydrocarbon receptor (AHR), is activated by environmental toxins. “Why this receptor is even present in body cells and which is its activation partner in the body, was yet unknown,” says Dr. Christiane Opitz, first author of the research article. “Kynurenin seems to have very similar effects as dioxin, but it is formed by the body itself,” said Professor Platten.
Yet another new discovery was presented by the group: The amino acid tryptophan was broken down in cancer cells by a specific enzyme called tryptophan dioxygenase, or TDO for short, which scientists had previously found primarily in liver cells. “It came as a surprise to us that TDO is also active in cancer cells and strongly so in particularly aggressive tumors.”
Searching for substances to specifically inhibit this metabolic pathway
The newly discovered metabolic pathway is a potential target for cancer treatment. The intention is to inhibit tumor growth and strengthen the immune system. “We will start searching for substances that specifically inhibit this metabolic pathway and may be used as potential antitumor drugs,” said Professor Wolfgang Wick envisioning the next steps ahead.Literature:
Heidelberg University Hospital and Medical Faculty of Heidelberg University Patient Care, Research and Teaching of International Standing Heidelberg University Hospital is among the largest and most renowned medical centers in Germany. The Medical Faculty of Heidelberg University ranges among the internationally relevant biomedical research institutes in Europe. The common goal is to develop new therapies and to apply them rapidly for the benefit of the patient. Hospitals and Faculty have approximately 10,000 employees and are active in training and qualification. In more than 50 departments, clinics and special departments with about 2,000 hospital beds, approximately 550,000 patients receive inpatient and outpatient treatment each year. There are currently about 3,600 aspiring doctors studying medicine in Heidelberg; the Heidelberg Curriculum Medicinale (HeiCuMed) is at the top of medical teaching and training in Germany.
Further reports about: > Cancer > DKFZ > Dioxin-like > German language > Germany > Nature Immunology > Public Relations > aggressive > amino acid > amino acid tryptophan > biomedical research > brain tumor > cancer cells > chemical engineering > chemical reaction > environmental toxin > immune system > malignant brain tumor > medical research > risk factor > tumor growth
Scientists uncover the role of a protein in production & survival of myelin-forming cells
19.07.2018 | Advanced Science Research Center, GC/CUNY
NYSCF researchers develop novel bioengineering technique for personalized bone grafts
18.07.2018 | New York Stem Cell Foundation
A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.
The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...
For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.
To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...
For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.
Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...
Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.
A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...
Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.
"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....
13.07.2018 | Event News
12.07.2018 | Event News
03.07.2018 | Event News
20.07.2018 | Power and Electrical Engineering
20.07.2018 | Information Technology
20.07.2018 | Materials Sciences